MindWalk Holdings (HYFT) Free Cash Flow (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Free Cash Flow of -$2.3 million for Q2 2026, down 39.33% year-over-year from -$3.8 million in Q2 2025, and down 9.91% quarter-over-quarter from -$2.1 million in Q1 2026.
MindWalk Holdings (HYFT) Free Cash Flow (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Free Cash Flow for 4 consecutive years, with -$2.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Free Cash Flow fell 39.33% year-over-year to -$2.3 million; the TTM figure through Apr 2026 stood at -$9.3 million (down 80.18% YoY), while the FY2026 annual figure was -$9.4 million, down 81.29% from the prior year.
- Free Cash Flow retreated to -$2.3 million in Q2 2026 per HYFT's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $207235.8 in Q4 2023 and bottomed at -$3.5 million in Q2 2023.
- Historically, Free Cash Flow has averaged -$1.7 million across 4 years, with a median of -$1.8 million in 2025.
- On a YoY basis, Free Cash Flow climbed as much as 63.81% in 2024 and fell as far as 869.97% in 2024.
- MindWalk Holdings' Free Cash Flow stood at $207235.8 in 2023, then plunged by 869.97% to -$1.6 million in 2024, then declined by 26.32% to -$2.0 million in 2025, then declined by 15.57% to -$2.3 million in 2026.
- Business Quant data shows HYFT's Free Cash Flow at -$2.3 million in Q2 2026, -$2.1 million in Q1 2026, and -$2.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.33 Mn |
| Apr 30, 2026 | -2.33 Mn |
| Jan 31, 2026 | -2.12 Mn |
| Jan 31, 2026 | -2.12 Mn |
| Oct 31, 2025 | -2.02 Mn |
| Oct 31, 2025 | -2.02 Mn |
| Jul 31, 2025 | -2.86 Mn |
| Jul 31, 2025 | -2.86 Mn |
| Apr 30, 2025 | -1.67 Mn |
| Apr 30, 2025 | -1.67 Mn |
| Jan 31, 2025 | -768,529.70 |
| Jan 31, 2025 | -768,529.70 |
| Oct 31, 2024 | -1.60 Mn |
| Oct 31, 2024 | -1.60 Mn |
| Jul 31, 2024 | -1.14 Mn |
| Jul 31, 2024 | -1.14 Mn |
| Apr 30, 2024 | -2.40 Mn |
| Apr 30, 2024 | -2.40 Mn |
| Jan 31, 2024 | -885,446.61 |
| Jan 31, 2024 | -885,446.61 |